77 related articles for article (PubMed ID: 8173234)
1. Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases.
Goldfarb RH; Whiteside TL; Basse PH; Lin WC; Vujanovic N; Herberman RB
Nat Immun; 1994; 13(2-3):131-40. PubMed ID: 8173234
[TBL] [Abstract][Full Text] [Related]
2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
3. Targeting of products of genes to tumor sites using adoptively transferred A-NK and T-LAK cells.
Goding S; Yang Q; Mi Z; Robbins PD; Basse PH
Cancer Gene Ther; 2007 May; 14(5):441-50. PubMed ID: 17273184
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anti-metastatic efficacy of IL-2 activated NK (A-NK) cells with novel benzothiazoles.
Goldfarb RH; Kitson RP; Brunson KW; Yoshino K; Hirota N; Kirii Y; Kotera Y; Inoue Y; Ohashi M
Anticancer Res; 1999; 19(3A):1663-7. PubMed ID: 10470098
[TBL] [Abstract][Full Text] [Related]
5. Targeting IL-2 to the endoplasmic reticulum confines autocrine growth stimulation to NK-92 cells.
Konstantinidis KV; Alici E; Aints A; Christensson B; Ljunggren HG; Dilber MS
Exp Hematol; 2005 Feb; 33(2):159-64. PubMed ID: 15676209
[TBL] [Abstract][Full Text] [Related]
6. Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene.
Finke S; Trojaneck B; Lefterova P; Csipai M; Wagner E; Kircheis R; Neubauer A; Huhn D; Wittig B; Schmidt-Wolf IG
Gene Ther; 1998 Jan; 5(1):31-9. PubMed ID: 9536262
[TBL] [Abstract][Full Text] [Related]
7. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.
Okada K; Nannmark U; Vujanovic NL; Watkins S; Basse P; Herberman RB; Whiteside TL
Cancer Res; 1996 Apr; 56(7):1599-608. PubMed ID: 8603408
[TBL] [Abstract][Full Text] [Related]
8. Endogenous IL-2 production by natural killer cells maintains cytotoxic and proliferative capacity following retroviral-mediated gene transfer.
Miller JS; Tessmer-Tuck J; Blake N; Lund J; Scott A; Blazar BR; Orchard PJ
Exp Hematol; 1997 Oct; 25(11):1140-8. PubMed ID: 9328450
[TBL] [Abstract][Full Text] [Related]
9. [Enhanced immune functions and antitumor activity of fibroblast-mediated interleukin-2 gene therapy].
Cao XT; Zhang WP; Tao Q
Zhonghua Yi Xue Za Zhi; 1995 Sep; 75(9):521-4, 573. PubMed ID: 8556540
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
Nakano H; Kishida T; Asada H; Shin-Ya M; Shinomiya T; Imanishi J; Shimada T; Nakai S; Takeuchi M; Hisa Y; Mazda O
J Gene Med; 2006 Jan; 8(1):90-9. PubMed ID: 16097036
[TBL] [Abstract][Full Text] [Related]
11. Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.
Reiter Z
Crit Rev Immunol; 1993; 13(1):1-34. PubMed ID: 8466640
[TBL] [Abstract][Full Text] [Related]
12. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer.
Li D; Ronson B; Guo M; Liu S; Bishop JS; Van Echo DA; O'Malley BW
Cancer Res; 2002 Jul; 62(14):4023-8. PubMed ID: 12124336
[TBL] [Abstract][Full Text] [Related]
14. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
Nannmark U; Hokland ME; Agger R; Christiansen M; Kjaergaard J; Goldfarb RH; Bagge U; Unger M; Johansson BR; Albertsson PA; Basse PH
In Vivo; 2000; 14(5):651-8. PubMed ID: 11125549
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-12 activates NK cells for IFN-gamma-dependent and NKT cells for IFN-gamma-independent antimetastatic activity.
Hafner M; Falk W; Echtenacher B; Männel DN
Eur Cytokine Netw; 1999 Dec; 10(4):541-8. PubMed ID: 10586121
[TBL] [Abstract][Full Text] [Related]
16. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin.
Goldfarb RH; Koelemij R; Muirhead KA; Ohlsson-Wilhelm BM; Gray BD; Kuppen PJ; Basse PH; al-Atrash G; Kitson RP
In Vivo; 2000; 14(1):101-4. PubMed ID: 10757065
[TBL] [Abstract][Full Text] [Related]
17. [Gene therapy and cancer: from concepts to clinical applications].
Jasmin C
Pathol Biol (Paris); 1993 Oct; 41(8):686-90. PubMed ID: 8290313
[TBL] [Abstract][Full Text] [Related]
18. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
19. Endothelial cell-based systemic gene therapy of metastatic melanoma.
Ojeifo JO; Lee HR; Rezza P; Su N; Zwiebel JA
Cancer Gene Ther; 2001 Sep; 8(9):636-48. PubMed ID: 11593332
[TBL] [Abstract][Full Text] [Related]
20. [Combined interleukin-2 and herpes simplex virus thymidine kinase gene therapy for head and neck squamous cell carcinoma].
Liu S; Liang C; Yang H; Xian J
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Dec; 36(6):426-9. PubMed ID: 12761956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]